With the rates of gout on the rise throughout the world, AstraZeneca and its Phase III therapy lesinurad could be lined up for a lead role in a growing market, welcome news for the sluggish pharma giant and its thin late-stage pipeline.
Japan's Astellas Pharma has seen enough of tivozanib, washing its hands of the once-promising cancer drug and putting an end to a three-year collaboration with Aveo Oncology.
I've been in the U.K. for a few days now, grabbing some meetings along the way after discussing valuations in biotechnology with a group of One Nucleus members at The Babraham Institute near Cambridge. And I've been thinking about this question a lot this week.
The biotech has struck a deal with little Prothelia and the University of Nevada, Reno, where it will step in and conduct development research on a protein replacement therapy for merosin-deficient congenital muscular dystrophy, or MDC1A.
Isis and partner Biogen Idec have kicked off a Phase II study of a spinal muscular atrophy treatment, part of the pair's $300 million alliance to advance antisense treatments.
When hedge fund veteran Martin Shkreli debuted Retrophin, his biotech play, more than few market watchers reacted with healthy skepticism and even open mockery. But now the company's plans to cash in with a rare-disease treatment have made it a hit with investors, with shares skyrocketing more than 40%.
French pharma outfit Pierre Fabre has teamed up with Indian biotech Aurigene to get its hands on a PD-1 checkpoint modulator, following a burgeoning trend in cancer drug development.
Novartis may have a long way to go before it's done cutting its blockbuster R&D budget. With a major strategic review underway, Novartis CEO Joe Jimenez told analysts that its massive drug research operation still offers a fresh source of spending cuts--even after a number of moves aimed at concentrating more of its R&D operations in the company's main research hubs in the U.S., Europe and Asia.
Lexington, MA's Concert Pharmaceuticals picked up $84 million in an upsized IPO, taking advantage of a prolonged boom for biotechs to replenish its R&D fund.
The FDA has rejected Durect's pain therapy Posidur, telling the biotech that investigators didn't provide sufficient data to prove that it could be safely administered. And regulators sent Durect back to the drawing board, instructing the company to do additional safety studies if it still wants to seek an approval for the drug, intended to ease postsurgical pain.
After an uncommonly bipolar review from FDA staff, The Medicines Co.'s cangrelor got an icy reception from a panel of agency advisers, who voted against granting approval for the company's blood-thinning treatment.
MedImmune, AstraZeneca's biologics arm, had inked a three-year agreement with the University of California, San Francisco, tapping the school's roster of scientists with hopes of finding promising projects across a bevy of disease areas.
AstraZeneca is again turning its back on some projects developed alongside Targacept, handing back several preclinical assets but holding onto a once-promising Alzheimer's disease treatment that may have some use in another indication.
Looking to wrap up its package of data to present to the FDA on its anal pain drug VEN 307, Ventrus Biosciences instead wound up with a failed Phase III study as a high placebo response wiped out the efficacy advantage that they were expecting.
Flexion Therapeutics and Eagle Pharmaceuticals are the latest drug developers to ride the bull market for biotechs into a public debut, bringing in a combined $115 million in a week that could see as many as 5 life sciences IPOs.
In an interview with Bloomberg, COO John Milligan says the big biotech outfit--which is expected to generate megablockbuster revenue from the newly approved Sovaldi for hep C--is pondering a head-to-head study to determine whether Letairis is better or worse than Actelion's recently approved lung drug Opsumit.
Third Rock Ventures has cut the ribbon on its latest startup, pledging $45 million to launch Cambridge, MA's Voyager Therapeutics, a gene therapy biotech with a promising platform for central nervous system treatments.
Biopharma's M&A rate jumped 11% in 2013 with the average deal value soaring 46%, according to PricewaterhouseCoopers, and analysts expect that healthy flow to continue into the new year.
Looking beyond the small-molecule drugs and biologic treatments that have dominated therapeutic development over the past generation, GlaxoSmithKline's all-encompassing R&D department is trying to get a jump on the future of medicine, and research chief Moncef Slaoui is betting that there's a great deal of promise in drug-mimicking electronics.